Pfizer's French branch director David Lepoittevin told French daily Le Parisien the first drug was a pill to be taken orally, while the the other was to be administered intravenously.
“Both are still at a very early stage of development," he said, adding that encouraging results for the pill candidate had promoted Pfizer to launch a clinical study on healthy adults to evaluate dose and tolerance.
Named PF-07321332, the oral antiviral is a protease inhibitor, a type of drug that prevents the virus from replicating in cells. Such drugs have been effective at treating viruses such as HIV and hepatitis C.
“Our intravenous antiviral candidate is also being tested in hospitalised patients with Covid,” Lepoittevin added.
After initial promising preclinical data, we’ve begun dosing healthy adult participants with our novel oral #antiviral investigational drug candidate as part of a Phase 1 #clinicaltrial. pic.twitter.com/AvgZs6njM6
— Pfizer Inc. (@pfizer) March 23, 2021
Along with Germany’s company BioNTech, Pfizer developed the first Covid-19 vaccine authorised for use in the United States. The vaccine now plays a leading role in vaccination campaigns in both the US and Europe.
On Friday, Pfizer-BioNTech asked for authorisation to use their Covid-19 vaccine on 12-15 year olds in the United States.
Lepoittevin did not offer any information as to when Pfizer’s new anti-Covid candidate drugs might arrive in pharmacies.
